Trials / Unknown
UnknownNCT02799550
Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
Treatment of Elderly Relapsed and/or Refractory CD19-positive Acute Lymphoblastic Leukemia by Infusions of Allogeneic CART-19
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 19 (CD19)-directed chimeric antigen receptor modified T cells (CART-19) infusions in patients with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL)
Detailed description
The relapsed and/or refractory B-ALL patients will receive infusions of allogeneic CART-19 within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily vindesine, mitoxantrone, cyclophosphamide, pegaspargase and dexamethasone, and no graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | allogeneic CART-19 | allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19) |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2019-05-01
- Completion
- 2020-05-01
- First posted
- 2016-06-15
- Last updated
- 2019-02-25
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02799550. Inclusion in this directory is not an endorsement.